We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01497379
First Posted: December 22, 2011
Last Update Posted: March 29, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Retina Implant AG
December 15, 2011
December 22, 2011
March 29, 2017
October 2011
January 2014   (Final data collection date for primary outcome measure)
  • Safety [ Time Frame: 1 year ]
    treatment shows no permanent damage of function and structures that have been functional before surgery and no permanent damage to health and/or well being of patients
  • Efficacy [ Time Frame: 1 year ]

    Activities of Daily Living & Mobility are significantly improved with implant-ON versus OFF, as shown via tests:

    • Activities of Daily Living tasks or
    • Recognition tasks or
    • Mobility or
    • a combination of the above
Same as current
Complete list of historical versions of study NCT01497379 on ClinicalTrials.gov Archive Site
  • Safety [ Time Frame: 1 year ]

    Patient long term safety:

    • stability of implant function
    • stability of body structure & function related to implant system
  • Efficacy [ Time Frame: 1 year ]

    Visual Acuity / Light-perception and/or Object-recognition are significantly improved with implant-ON versus OFF as shown via:

    • FrACT or
    • BaLM or
    • Grating test (e.g. BaGA) and/or Quality of life
    • Quality of life (questionnaire) or
    • a combination of the above
Same as current
Not Provided
Not Provided
 
Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients
Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients: A Prospective Mono- & Multicenter Clinical Study Based on Randomized Intra-individual Implant Activation in Degenerative Retinal Disease Patients.
Patients who are legally blind, caused by retinal degeneration of photoreceptor rods & cones (e.g. Retinitis pigmentosa), receive a subretinal implant to restore vision partially.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
  • Retinal Degeneration
  • Retinitis Pigmentosa
  • Procedure: surgical implantation of subretinal device
    surgical implantation of subretinal device
    Other Name: Retinal implant, subretinal implant
  • Procedure: surgical implantation of subretinal device
    intra-individual implant OFF
    Other Name: Retinal implant, subretinal implant
  • Experimental: intra-individual implant ON
    intra-individual implant activation
    Intervention: Procedure: surgical implantation of subretinal device
  • Placebo Comparator: intra-individual implant OFF
    intra-individual implant deactivation
    Intervention: Procedure: surgical implantation of subretinal device
Stingl K, Bartz-Schmidt KU, Besch D, Chee CK, Cottriall CL, Gekeler F, Groppe M, Jackson TL, MacLaren RE, Koitschev A, Kusnyerik A, Neffendorf J, Nemeth J, Naeem MA, Peters T, Ramsden JD, Sachs H, Simpson A, Singh MS, Wilhelm B, Wong D, Zrenner E. Subretinal Visual Implant Alpha IMS--Clinical trial interim report. Vision Res. 2015 Jun;111(Pt B):149-60. doi: 10.1016/j.visres.2015.03.001. Epub 2015 Mar 23.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2
January 2015
January 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Hereditary retinal degeneration of the outer retinal layers i.e. photoreceptor rods & cones.
  • Pseudophakia
  • Angiography shows retinal vessels adequately perfused, despite pathological RP condition.
  • Age between 18 and 78 years.
  • Blindness (at least monocular) i.e. visual functions not appropriate for localization of objects, self sustained navigation and orientation (impaired light localization or worse).
  • Ability to read normal print in earlier life, optically corrected without magnifying glass.
  • Willing and able to give written informed consent in accordance to EN ISO 14155 (section 6.7) and local legislation prior to participation in the study. Able to perform the study during the full time period of one year

Exclusion Criteria:

  • Period of appropriate visual functions < 12 years / lifetime.
  • Optical Coherence Tomography (OCT) shows significant retina edema &/or scar tissue within target region for implant.
  • Retina detected as too thin to expect required rest-functionality of inner retina as shown via Optical Coherence Tomography (OCT).
  • Lack of inner-retinal function, as determined by Electrically Evoked Phosphenes (EEP).
  • Heavy clumped pigmentation at posterior pole
  • Any other ophthalmologic disease with relevant effect upon visual function (e.g. glaucoma, optic neuropathies, trauma, diabetic retinopathy, retinal detachment).
  • Amblyopia reported earlier in life on eye to be implanted
  • Systemic diseases that might imply considerable risks with regard to the surgical interventions and anaesthesia (e.g. cardiovascular/ pulmonary diseases, severe metabolic diseases).
  • Neurological and/or psychiatric diseases (e.g. M. Parkinson, epilepsy, depression).
  • Hyperthyroidism or hypersensitivity to iodine
  • Women who are pregnant or nursing, or women of childbearing potential who are not willing to use a medically acceptable means of birth control for the duration of the study, or women unwilling to perform a pregnancy test before entering the study.
  • Participation in another interventional clinical trial within the past 30 days.
Sexes Eligible for Study: All
18 Years to 78 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Hong Kong
 
 
NCT01497379
HKCTR-1198
RI-MC-CT-2009 ( Registry Identifier: Clinicaltrials.gov )
Yes
Not Provided
Not Provided
Retina Implant AG
Retina Implant AG
Not Provided
Principal Investigator: David Wong, Prof., MD Chair Professor in Ophthalmology Eye Institute
Retina Implant AG
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP